Progenics Pharma (NASDAQ: PGNX) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.68 million.

NDA (New Drug Application) for AZEDRA® Expected to be Submitted to U.S. Food and Drug Administration (FDA) in August 2017

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.